Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013

Sponsor
Agence de Médecine Préventive, France (Other)
Overall Status
Unknown status
CT.gov ID
NCT01747369
Collaborator
Region Sanitaire des Savanes, Togo (Other), Ministere de la Sante et de la Promotion Sociale, Togo (Other), Institut National d'Hygiene, Togo (Other), Centre Muraz (Other), Fondation Mérieux, France (Other), Pfizer (Industry)
2,000
5
86
400
4.7

Study Details

Study Description

Brief Summary

The aim of this study is to estimate the burden of disease due to pneumococci, other bacteria and viruses in the African meningitis belt prior to pneumococcal conjugate vaccine introduction and to estimate the population impact of the vaccine after its implementation in 2014. In a defined population of a sanitary district in northern Togo, during the period 2010 to 2017, investigators enroll patients of all ages with suspected pneumonia requiring hospitalization or suspected bacterial meningitis. Patients are evaluated by bacteriology and molecular biology techniques on blood, cerebro-spinal fluid, nasal aspirates and by chest X-ray.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Actual Study Start Date :
    Apr 1, 2010
    Anticipated Primary Completion Date :
    Jun 1, 2017
    Anticipated Study Completion Date :
    Jun 1, 2017

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of pneumococcal pneumonia requiring hospitalisation, confirmed by blood culture or PCR analysis of blood [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    2. Incidence of pneumococcal meningitis, confirmed by culture or PCR on cerebro-spinal fluid [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    Secondary Outcome Measures

    1. Incidence of radiologically confirmed pneumonia requiring hospitalisation [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    2. Incidence of suspected pneumonia requiring hospitalisation with elevated C-reactive protein serum concentration (<40mg/l) [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    3. Incidence of suspected pneumonia requiring hospitalisation with reduced oxygen saturation (<90%) [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    4. Incidence of pneumonia of other bacterial or viral etiology requiring hospitalisation [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    5. Incidence of acute meningitis of other bacterial etiology [Subjects will be enrolled on admission to hospital and followed for the duration of hospitalization (median duration 6 days)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Pneumonia surveillance:
    Inclusion Criteria:
    • resident of Tône sanitary district - requiring hospitalisation for at least one night for clinical pneumonia syndrome

    • hospitalised in a study site during the study period

    Exclusion Criteria:
    • absence of informed consent by patient or legal tutor
    Meningitis surveillance:
    Inclusion Criteria:
    • resident of Tône sanitary district

    • presenting clinical signs of acute bacterial meningitis

    • hospitalised in a study site during the study period

    Exclusion Criteria:
    • absence of informed consent by patient or legal tutor

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre médico-social (CMS) Cinkassé Savanes region Togo
    2 Centre Hospitalier Régional (CHR) Savanes Dapaong Savanes region Togo
    3 Clinique Win' Pang Dapaong Savanes region Togo
    4 Hôpital d'enfants Yendubé Dapaong Savanes region Togo
    5 Polyclinique Dapaong Savanes region Togo

    Sponsors and Collaborators

    • Agence de Médecine Préventive, France
    • Region Sanitaire des Savanes, Togo
    • Ministere de la Sante et de la Promotion Sociale, Togo
    • Institut National d'Hygiene, Togo
    • Centre Muraz
    • Fondation Mérieux, France
    • Pfizer

    Investigators

    • Principal Investigator: Jennifer C Moïsi, PhD, Agence de Médecine Préventive

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Agence de Médecine Préventive, France
    ClinicalTrials.gov Identifier:
    NCT01747369
    Other Study ID Numbers:
    • PneumoTone
    First Posted:
    Dec 11, 2012
    Last Update Posted:
    Mar 6, 2017
    Last Verified:
    Mar 1, 2017

    Study Results

    No Results Posted as of Mar 6, 2017